XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						June 30, 2023																								December 31, 2022
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir						$	10,720					$	(6,700)					$	—					$	4,020					$	10,720					$	(6,350)					$	—					$	4,370
Intangible asset – axicabtagene ciloleucel						7,110						(2,111)						—						4,999						7,110						(1,908)						—						5,202
Intangible asset – Trodelvy(1)						11,730						(1,462)						—						10,268						5,630						(973)						—						4,657
Intangible asset – Hepcludex						845						(201)						—						644						845						(158)						—						687
Other						1,489						(792)						1						698						1,489						(733)						1						758
Total finite-lived assets						31,894						(11,265)						1						20,630						25,794						(10,121)						1						15,674
Indefinite-lived assets – IPR&D(1)						7,120						—						—						7,120						13,220						—						—						13,220
Total intangible assets						$	39,014					$	(11,265)					$	1					$	27,750					$	39,014					$	(10,121)					$	1					$	28,894

_______________________________

(1)    In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:

						June 30, 2023																								December 31, 2022
(in millions)						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount						Gross  Carrying Amount						Accumulated Amortization						Foreign Currency Translation Adjustment						Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir						$	10,720					$	(6,700)					$	—					$	4,020					$	10,720					$	(6,350)					$	—					$	4,370
Intangible asset – axicabtagene ciloleucel						7,110						(2,111)						—						4,999						7,110						(1,908)						—						5,202
Intangible asset – Trodelvy(1)						11,730						(1,462)						—						10,268						5,630						(973)						—						4,657
Intangible asset – Hepcludex						845						(201)						—						644						845						(158)						—						687
Other						1,489						(792)						1						698						1,489						(733)						1						758
Total finite-lived assets						31,894						(11,265)						1						20,630						25,794						(10,121)						1						15,674
Indefinite-lived assets – IPR&D(1)						7,120						—						—						7,120						13,220						—						—						13,220
Total intangible assets						$	39,014					$	(11,265)					$	1					$	27,750					$	39,014					$	(10,121)					$	1					$	28,894

_______________________________

(1)    In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.

Summary of Estimated Future Amortization Expense

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of June 30, 2023:

(in millions)						Amount
2023 (remaining six months)						$	1,196
2024						2,392
2025						2,386
2026						2,378
2027						2,378
Thereafter						9,900
Total						$	20,630

X

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2

+ Details

Name:	us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b),(d)
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3

+ Details

Name:	us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2

+ Details

Name:	us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration